Shaily Engineering Plastics will host a group meeting with investors and analysts on August 21, 2026, at 10:00 am in Vadodara, Gujarat.

The company issued the intimation on August 17, 2026, pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Officials from the firm will lead the discussions during the scheduled interaction.

Meeting details

The event is classified as a group meeting. The venue is located in Vadodara, Gujarat. The company emphasised that no unpublished price-sensitive information (UPSI) is intended to be discussed during the interaction.

Harish Punwani, Company Secretary and Compliance Officer, signed the disclosure. The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company.

Shaily Engineering Plastics Limited reported strong financial performance for the quarter ended June 30, 2026, with consolidated revenue rising 14% year-on-year to ₹281 crore from ₹247 crore in Q1FY26. Profit after tax (PAT) increased 17% to ₹48 crore, up from ₹41 crore in the previous year, while EBITDA grew 18% to ₹83 crore. The company’s EBITDA margin expanded by 120 basis points to 29.7%, and PAT margin improved by 40 basis points to 17.1%.

The Board of Directors approved the unaudited standalone and consolidated financial results during a meeting held on August 8, 2026. The session also fixed September 11, 2026, as the record date for the final dividend for FY25 and reappointed Amit Mahendra Sanghvi as Managing Director, effective from October 1, 2026, to September 30, 2031, subject to shareholder approval.

Segment Performance

The Healthcare segment emerged as the company’s largest business unit, contributing approximately 51% of consolidated revenue. Segment revenue surged 85% year-on-year to ₹142 crore, driven by robust demand for pen injectors used in GLP-1 and other chronic therapies. Management noted that six of the eight device platforms are now fully commercial and sold across global markets.

Conversely, the Consumer segment faced headwinds, with revenue declining 24% year-on-year to ₹116 crore due to softer demand in home furnishings across Europe and the United States. This segment accounted for around 41% of total revenue. The Industrial segment maintained growth momentum, increasing 25% year-on-year to ₹23 crore, supported by new customer additions in engineering applications, consumer electronics, and automotive sectors.

Operational Highlights and Capacity Expansion

Machine utilization improved to 50.2% in Q1FY27, up from 48.7% in the corresponding quarter last year. Exports accounted for approximately 58% of consolidated revenue, down from 76% in Q1FY26, primarily due to the growing contribution of the Healthcare business where products are supplied to global markets through Indian pharmaceutical customers.

Management highlighted significant progress in capacity expansion. An additional 25 million pen capacity is expected to become operational by end-September 2026, taking total installed pen injector capacity to approximately 75 million pens per annum. In Q1FY27, the company delivered close to 9 million devices, with 50% to 60% attributed to GLP-1 therapies.

Strategic Developments

Shaily Engineering Plastics secured regulatory approvals for generic Semaglutide in Canada and Brazil, leading to orders for injector pen supplies from pharmaceutical partners. The company also signed two new platform projects, strengthening its long-term product pipeline. Dedicated heads of business development have been appointed for Europe and North America to pursue partnerships with major global pharmaceutical companies.

In the Industrial segment, the company secured a global project from an FMCG customer and won new business in LED lighting. It also onboarded a new customer for five consumer electronic components, with commercial supply expected before the end of the financial year. Additionally, the company plans to invest approximately ₹5 crore in existing facilities for semiconductor trays, with initial revenue expected in Q4FY27.

What the Numbers Show

The shift in export mix highlights the structural change in Shaily’s business model. While traditional export-oriented Consumer revenue declined, the Healthcare segment’s growth—largely sold through domestic pharma partners who then export—reduced the direct export percentage from 76% to 58%. Despite this, the overall revenue base expanded, indicating that domestic partnerships are effectively capturing global demand without requiring direct export logistics for every unit.

Gross margins faced sequential pressure due to post-March commodity price increases and elevated freight costs, including premium airlift incidents. However, management indicated that pass-through mechanisms would normalize margins by Q3FY27. The company clarified that its pricing strategy is market-driven rather than cost-plus, relying on annual price reviews linked to inflation and polymer indices.